secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2026-07-27T11:01:41+00:00
Accession:  0001628280-26-049661
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 receives Australian TGA clearance for CMP-002 Phase 1/2 trial; triggers $50M second closing
--------------------------------------------------------------------------------

- TGA and HREC clearance to initiate first-in-human Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder.
- Milestone triggers second closing of September 2025 private placement; up to $50M gross proceeds.
- Second closing expected on or about August 3, 2026; up to 32.7M shares (or pre-funded warrants) to be issued.
- Investors committed include Coastlands Capital, Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures, Adage, Trails Edge, CURE SYNGAP1.
- Australia selected as first site; company pursuing additional international regulatory filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000162828026049661/0001628280-26-049661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000162828026049661/camp-20260727.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-049661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer